{"id":524033,"date":"2021-08-05T08:04:35","date_gmt":"2021-08-05T12:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/"},"modified":"2021-08-05T08:04:35","modified_gmt":"2021-08-05T12:04:35","slug":"ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/","title":{"rendered":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d"},"content":{"rendered":"
\n

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (\u201cEnsysce\u201d or the \u201cCompany\u201d) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.<\/em><\/p>\n

The invention comprises\u00a0a method for controlled release of amphetamine to a patient using the Trypsin-Activated Abuse Protection (TAAP) platform of Ensysce, which has been applied previously to the company\u2019s opioid products, to reduce abuse. The allowed claims also cover administering\u00a0these\u00a0amphetamine prodrugs with a GI enzyme inhibitor, in accordance with Ensysce\u2019s Multi-Pill Abuse Resistance (MPAR\u2122) platform, providing overdose protection to this class of agents.<\/p>\n

\u201cWe are pleased to be growing our patent portfolio,\u201d said Ensysce CEO Dr. Lynn Kirkpatrick. \u201cThis issuance provides the company with another possibility to build our pipeline of products for ADHD indications. We believe that our TAAP and MPAR\u2122 platforms applied to this category of prescription drugs are unique in the industry.\u201d<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains certain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication. Such factors can be found in Ensysce\u2019s most recent annual report on Form 10-K, subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC\u2019s website at www.sec.gov, and also in the Form S-4 and Ensysce\u2019s definitive proxy statement\/prospectus filed on June 16, 2021. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect the Company. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Ensysce undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.<\/p>\n

\n About Ensysce Biosciences (NASDAQ: ENSC)<\/strong>
\n
Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR\u2122) platforms, the Company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce\u2019s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Gateway Investor Relations
Matt Glover, Alex Thompson
(949) 574-3860
Ensysce@gatewayir.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (\u201cEnsysce\u201d or the \u201cCompany\u201d) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof. The invention comprises\u00a0a method for controlled release of amphetamine to a patient using the Trypsin-Activated Abuse Protection (TAAP) platform of Ensysce, which has been applied previously to the company\u2019s opioid products, to reduce abuse. The allowed claims also cover administering\u00a0these\u00a0amphetamine prodrugs with a GI enzyme inhibitor, in accordance with Ensysce\u2019s Multi-Pill Abuse Resistance … <\/p>\n

Continue reading “Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-524033","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnsysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (\u201cEnsysce\u201d or the \u201cCompany\u201d) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof. The invention comprises\u00a0a method for controlled release of amphetamine to a patient using the Trypsin-Activated Abuse Protection (TAAP) platform of Ensysce, which has been applied previously to the company\u2019s opioid products, to reduce abuse. The allowed claims also cover administering\u00a0these\u00a0amphetamine prodrugs with a GI enzyme inhibitor, in accordance with Ensysce\u2019s Multi-Pill Abuse Resistance … Continue reading "Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T12:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d\",\"datePublished\":\"2021-08-05T12:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/\"},\"wordCount\":526,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/\",\"name\":\"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=\",\"datePublished\":\"2021-08-05T12:04:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/","og_locale":"en_US","og_type":"article","og_title":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk","og_description":"SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (\u201cEnsysce\u201d or the \u201cCompany\u201d) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof. The invention comprises\u00a0a method for controlled release of amphetamine to a patient using the Trypsin-Activated Abuse Protection (TAAP) platform of Ensysce, which has been applied previously to the company\u2019s opioid products, to reduce abuse. The allowed claims also cover administering\u00a0these\u00a0amphetamine prodrugs with a GI enzyme inhibitor, in accordance with Ensysce\u2019s Multi-Pill Abuse Resistance … Continue reading \"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T12:04:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d","datePublished":"2021-08-05T12:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/"},"wordCount":526,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/","name":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=","datePublished":"2021-08-05T12:04:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzAxNCM0MzQxODY0IzIyMDk0NjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-patent-entitled-compositions-comprising-enzyme-cleavable-amphetamine-prodrugs-and-inhibitors-th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled \u201cCompositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof\u201d"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=524033"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524033\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=524033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=524033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=524033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}